<SEC-DOCUMENT>0001279569-22-000371.txt : 20220310
<SEC-HEADER>0001279569-22-000371.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310105255
ACCESSION NUMBER:		0001279569-22-000371
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220309
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		22727899

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>essa8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:EPI="http://essapharmaceuticals.com/20220309">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_EPI_essapharmaceuticals.com_20220309 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20220309_20220309 -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001633932 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-03-09to2022-03-09" name="dei:EntityCentralIndexKey">0001633932</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-03-09to2022-03-09" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-03-09to2022-03-09" id="xdx2ixbrl0012" name="dei:EntityIncorporationStateCountryCode">A1</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="epi-20220309.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-03-09to2022-03-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-09</xbrli:startDate>
        <xbrli:endDate>2022-03-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: Black 3.5pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center">__________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_90E_edei--DocumentType_c20220309__20220309_zclr08ezIKOj"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center">__________</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of report (Date of earliest event reported): <span id="xdx_902_edei--DocumentPeriodEndDate_c20220309__20220309_zXyI9rjeYhpf"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March
9, 2022</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center">__________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_90B_edei--EntityRegistrantName_c20220309__20220309_z4Hf6YsO2zI1"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" name="dei:EntityRegistrantName">ESSA Pharma Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center">__________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 40%; padding-right: 5.75pt; padding-left: 5.75pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_dxL_c20220309__20220309_zGyC5YBAeo71" title="::XDX::A1"><span style="-sec-ix-hidden: xdx2ixbrl0012">British Columbia</span></span>, Canada</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction of incorporation)</p></td>
    <td style="width: 27%; padding-right: 5.75pt; padding-left: 5.75pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_90B_edei--EntityFileNumber_c20220309__20220309_zXSz5Wi4mcDh"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" name="dei:EntityFileNumber">001-37410</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Commission File Number)</p></td>
    <td style="width: 33%; padding-right: 5.75pt; padding-left: 5.75pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20220309__20220309_zQtM5EyfqLl8"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" name="dei:EntityTaxIdentificationNumber">47-2569713</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(IRS Employer Identification No.)</p></td></tr>
  <tr>
    <td style="font: 11pt Times New Roman, Times, Serif; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&#160;</td>
    <td style="font: 11pt Times New Roman, Times, Serif; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&#160;</td>
    <td style="font: 11pt Times New Roman, Times, Serif; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&#160;</td></tr>
  <tr>
    <td colspan="2" style="padding-right: 5.75pt; padding-left: 5.75pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20220309__20220309_zwQh78wKfuN2"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" name="dei:EntityAddressAddressLine1">Suite 720</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressAddressLine2_c20220309__20220309_zeVmIjU9h829"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" name="dei:EntityAddressAddressLine2">999 West Broadway</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressCityOrTown_c20220309__20220309_zbTDEA27OtZ1"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" name="dei:EntityAddressCityOrTown">Vancouver</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressStateOrProvince_c20220309__20220309_zFEPZKfPWQea"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">British
    Columbia</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressCountry_c20220309__20220309_zqNy08s7i3b1"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Canada</ix:nonNumeric> </span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</p></td>
    <td style="padding-right: 5.75pt; padding-left: 5.75pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressPostalZipCode_c20220309__20220309_zFdGd8ZVtb97"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" name="dei:EntityAddressPostalZipCode">V5Z 1K5</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Zip Code)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&#8217;s telephone number, including area
code: <b>(<span id="xdx_904_edei--CityAreaCode_c20220309__20220309_zp5lelDUe40f"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" name="dei:CityAreaCode">778</ix:nonNumeric></span>) <span id="xdx_900_edei--LocalPhoneNumber_c20220309__20220309_zYi4J11QxJO3"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" name="dei:LocalPhoneNumber">331-0962</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center">__________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><span id="xdx_902_edei--WrittenCommunications_c20220309__20220309_zr8pC4amxda2"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span>&#9;Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><span id="xdx_90C_edei--SolicitingMaterial_c20220309__20220309_zsv9hSbd9lCl"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span> Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20220309__20220309_z0HeHkkO0Ypi"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span>&#9;Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20220309__20220309_z6BitdqLm2rk"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span>&#9;Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 43%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: center"><b>Title of
    each class</b></p></td>
    <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: center"><b>Trading
    Symbol(s)</b></p></td>
    <td style="width: 42%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: center"><b>Name of
    each exchange on which registered</b></p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20220309__20220309_zwkQtoeX6y23"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" name="dei:Security12bTitle">Common Shares</ix:nonNumeric></span>, no par value</span></td>
    <td style="font: 11pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_edei--TradingSymbol_c20220309__20220309_zIMrs9De6uni"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" name="dei:TradingSymbol">EPIX</ix:nonNumeric></span></span></td>
    <td style="font: 11pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_edei--SecurityExchangeName_c20220309__20220309_ziQgVtYusRG5"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">Emerging growth company <span id="xdx_905_edei--EntityEmergingGrowthCompany_c20220309__20220309_znyMUYHZkJQj"><ix:nonNumeric contextRef="From2022-03-09to2022-03-09" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. &#9744;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 3.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 5.07&#9; &#9; Submission of Matters to a Vote of Security Holders.</b></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following information is filed pursuant to Item
5.07, &#8220;Submission of Matter to a Vote of Security Holders.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 9, 2022, ESSA Pharma Inc. (the &#8220;Company&#8221;),
held its 2022 annual general meeting of shareholders (the &#8220;Meeting&#8221;). A total of 33,303,014 of the holders of the Company&#8217;s
common shares were present or represented by proxy at the meeting, representing approximately 75.66% of the Company&#8217;s 44,015,870
common shares that were outstanding and entitled to vote at the Meeting as of the record date of January 18, 2022. Set forth below are
the matters acted upon by the Company&#8217;s shareholders at the Meeting, and the final voting results on each matter. Each of the proposals
are described in further detail in the Company&#8217;s definitive proxy statement dated January 28, 2022, filed with the Securities and
Exchange Commission on January 28, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Proposal 1: Setting the Number of Directors</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="margin-left: auto; width: 70%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; width: 55%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="font: 11pt Times New Roman, Times, Serif; width: 45%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">29,383,465</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Against </b></span></td>
    <td style="font: 11pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">23,291</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="font: 11pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td>
    <td style="font: 11pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">3,896,258</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Proposal 2: Election of Directors </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Nominee</b></span></td>
    <td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Votes For</b></span></td>
    <td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>% Votes For</b></span></td>
    <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Votes Withheld</b></span></td>
    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>% Votes Withheld</b></span></td>
    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">David R. Parkinson</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,377,984</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.90%</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,772</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.10%</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">3,896,258</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">Richard M. Glickman</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,253,929</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.48%</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">152,827</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.52%</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">3,896,258</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">Gary Sollis</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,596,127</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.24%</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">810,629</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.76%</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">3,896,258</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">Franklin M. Berger</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,684,413</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70.34%</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,722,343</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.66%</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">3,896,258</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">Scott Requadt</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,369,580</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.87%</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,176</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.13%</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">3,896,258</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">Marella Thorell</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,847,371</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.10%</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">559,385</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.90%</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">3,896,258</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">Alex Martin</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,914,856</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91.53%</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,491,900</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.47%</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">3,896,258</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">Sandy Zweifach</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,387,996</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.94%</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,760</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.06%</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">3,896,258</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Proposal 3: Advisory Vote on the Compensation
of the Company&#8217;s Named Executive Officers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; margin-left: auto; width: 70%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="width: 55%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 45%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">29,353,176</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Against </b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">53,580</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">3,896,258</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Proposal 4: Advisory Vote on the Frequency of
Solicitation of Advisory Shareholder Approval of Executive Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; margin-left: auto; width: 70%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="width: 55%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 45%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">29,403,169</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Against </b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">3,587</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">3,896,258</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Proposal 5: Appointment and Remuneration of
Auditors</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; margin-left: auto; width: 70%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="width: 55%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 45%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">33,275,069</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Against </b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">27,945</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">0</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Proposal 6: Approval of Omnibus Incentive Plan
Amendment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; margin-left: auto; width: 70%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="width: 55%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 45%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">28,162,684</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Against </b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">1,244,072</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">3,896,258</span></td></tr>
  </table>
<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 14%"><span style="font-size: 10pt"><b>Item 9.01</b></span></td>
    <td style="width: 86%"><span style="font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>(d) Exhibits</b></span></td></tr>
  </table>
<p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 16%">
    <p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exhibit No.</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 82%">
    <p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Description</b></p></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><a href="ex991.htm">10.1</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="ex991.htm">Essa Pharma Inc. 2022 Omnibus Incentive Plan.</a></span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>

<!-- Field: Page; Sequence: 3 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 311.85pt; text-indent: -311.85pt">&#9;<span style="text-decoration: underline"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt"><b><i>ESSA PHARMA INC.</i></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="2" style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">Date: March 10, 2022</span></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; width: 41%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">/s/ David Wood</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">Name: &#160;David Wood</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">Title:&#9;Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 311.85pt; text-indent: -311.85pt"><span style="text-decoration: underline"></span></p>

<p style="font: 11pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZi6YpuuhOixaxihQRt9GOEmwzZRL/juQtjS3iMDAM733vCTEQOS1MjQyHWVnADpu21h6hxDMy2hMGR7ZcpRBuiRfjPGvru/cHZhQYDMx4GKtjEDrr3TisUpDJKJYjpUBOUpXAdC2ir56RPZsKrTe6Bm0r2DK1bNBrfvUJO/0kS82rq9ojO0M2hXgoe/kNSsYKNnTXD+Krg6LIRDToJhI506391tycpwbmNTahy/Xof6MPC8BJNA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>OMNIBUS INCENTIVE PLAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: center">ESSA PHARMA INC.<BR>
2022 OMNIBUS INCENTIVE PLAN</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><B>Section 1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purpose
of Plan</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">The name of the Plan is the
ESSA Pharma Inc. 2022 Omnibus Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;). The purposes of the Plan are to provide an additional incentive
to selected officers, employees, non-employee directors and consultants of the Company or its Affiliates whose contributions are essential
to the growth and success of the business of the Company and its Affiliates, in order to strengthen the commitment of such persons to
the Company, to motivate such persons to faithfully and diligently perform their responsibilities, and to attract and retain competent
and dedicated persons for long-term growth and profitability. To accomplish such purposes, the Plan provides that the Company may grant
Options, Share Appreciation Rights, Restricted Shares, Restricted Share Units, Share Bonuses, Other Share-Based Awards, Cash Awards or
any combination of the foregoing.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><B>Section 2. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">For purposes of the Plan, the
following terms shall be defined as set forth below:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Administrator</U>&rdquo;
means the Board, or, if and to the extent the Board does not administer the Plan, the Committee in accordance with <U>Section&nbsp;3</U>
hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Affiliate</U>&rdquo;
means a Person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control
with, the Person specified.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Award</U>&rdquo;
means any Option, Share Appreciation Right, Restricted Shares, Restricted Share Unit, Share Bonus, Other Share-Based Award or Cash Award
granted under the Plan.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Award Agreement</U>&rdquo;
means any written agreement, contract or other instrument or document evidencing an Award.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Base Price</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;8(b)</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Beneficial Owner</U>&rdquo;
(or any variant thereof) has the meaning defined in Rule 13d-3 under the Exchange Act.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Board</U>&rdquo;
means the Board of Directors of the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Cash Award</U>&rdquo;
means an Award granted pursuant to <U>Section&nbsp;12</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Cause</U>&rdquo;
has the meaning assigned to such term in the Award Agreement or in any individual employment, service or severance agreement with the
Participant or, if any such agreement does not define &ldquo;Cause,&rdquo; Cause means: (<U>i</U>) the indictment of, or conviction of,
or entering a please of guilty or <I>nolo contendere</I> by, the Participant for a crime constituting a felony or in respect of any act
of fraud or dishonesty; (<U>ii</U>) the commission of an act of fraud or dishonesty by the Participant in the course of the Participant&rsquo;s
employment with or service to the Company and its Affiliates; (<U>iii</U>) any misappropriation or embezzlement of the property of the
Company or any of its Affiliates; (<U>iv</U>) the Participant has failed to perform his or her material duties, and such failure has not
been cured after a period of thirty (30) days&rsquo; notice from the Company; (<U>v</U>) gross negligence or willful misconduct in connection
with the Participant&rsquo;s performance of his or her duties in connection with the Participant&rsquo;s employment by or service to the
Company and its Affiliates; or (<U>vi</U>) the Participant&rsquo;s failure to comply with (<U>x</U>) any of the restrictive covenants
to which the Participant is subject, or (<U>y</U>) any material policies or procedures of the Company and its Affiliates as in effect
from time to time; <U>provided</U>, that the Participant shall have been delivered a copy of such policies or notice that they have been
posted on a Company website prior to such compliance failure.</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Change in Capitalization</U>&rdquo;
means any (<U>i</U>) merger, amalgamation, consolidation, reclassification, recapitalization, spin-off, spin-out, repurchase or other
reorganization or corporate transaction or event, (<U>ii</U>) special or extraordinary dividend or other extraordinary distribution (whether
in the form of cash, Common Shares, or other property), share split, reverse share split, subdivision or consolidation, (<U>iii</U>) combination
or exchange of shares, or (<U>iv</U>) other change in corporate structure, which, in any such case, the Committee determines, in its sole
discretion, affects the Common Shares such that an adjustment pursuant to <U>Section&nbsp;5</U> hereof is appropriate.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Change in Control</U>&rdquo;
<FONT STYLE="font-family: TimesNewRoman">means, unless otherwise defined in an Award Agreement, an event set forth in any one of the following
paragraphs shall have occurred:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: windowtext">any
Person (or any group of Persons acting together which would constitute a &ldquo;group&rdquo; for purposes of Section 13(d) of the Exchange
Act), other than the Company or its respective Affiliates, is or becomes the Beneficial Owner, directly or indirectly, of securities of
the Company (not including in the securities Beneficially Owned by such Person or any securities acquired directly from the Company or
any Affiliate thereof) representing fifty percent (50%) or more of the combined voting power of the Company&rsquo;s then outstanding securities,
excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in clause&nbsp;(I) of paragraph&nbsp;(3)
below; </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: windowtext">the
following individuals cease for any reason to constitute a majority of the number of directors then serving on the Board: individuals
who, on the date hereof, constitute the Board and any new director whose appointment or election by the Board or nomination for election
by the Company&rsquo;s shareholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in
office who either were directors on the date hereof or whose appointment, election or nomination for election was previously so approved
or recommended;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: windowtext">there
is consummated a merger, amalgamation or consolidation of the Company or any direct or indirect Subsidiary with any other corporation
or other entity, other than (<U>I</U>) a merger, amalgamation or consolidation (<U>A</U>) which results in the voting securities of the
Company outstanding immediately prior to such merger, amalgamation or consolidation continuing to represent (either by remaining outstanding
or by being converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any
trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary, fifty percent (50%) or
more of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately
after such merger, amalgamation or consolidation and (<U>B</U>) immediately following which the individuals who comprise the Board immediately
prior thereto constitute at least a majority of the board of directors of the Company or the entity surviving such merger, amalgamation
or consolidation, or, if the Company or the entity surviving such merger, amalgamation or consolidation is then a subsidiary, the ultimate
parent thereof, or (<U>II</U>) a merger, amalgamation or consolidation effected to implement a recapitalization of the Company (or similar
transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including
in the securities Beneficially Owned by such Person any securities acquired directly from the Company or its Affiliates) representing
50% or more of the combined voting power of the Company&rsquo;s then outstanding securities; or</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: windowtext">the
shareholders of the Company approve a plan of complete liquidation or dissolution of the Company or there is consummated an agreement
for the sale or disposition by the Company of all or substantially all of the Company&rsquo;s assets, other than (<U>A</U>) a sale or
disposition by the Company of all or substantially all of the Company&rsquo;s assets to an entity, at least fifty percent (50%) of the
combined voting power of the voting securities of which are owned by shareholders of the Company following the completion of such transaction
in substantially the same proportions as their ownership of the Company immediately prior to such sale or (<U>B</U>)&nbsp;a sale or disposition
of all or substantially all of the Company&rsquo;s assets immediately following which the individuals who comprise the Board immediately
prior thereto constitute at least a majority of the board of directors of the entity to which such assets are sold or disposed or, if
such entity is a subsidiary, the ultimate parent thereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">Notwithstanding the foregoing,
(<U>i</U>) a Change in Control shall not be deemed to have occurred by virtue of the consummation of any transaction or series of integrated
transactions immediately following which the holders of Common Shares immediately prior to such transaction or series of transactions
continue to have substantially the same proportionate ownership in an entity which owns all or substantially all of the assets of the
Company immediately following such transaction or series of transactions and (<U>ii</U>) for each Award that constitutes deferred compensation
under Section 409A of the Code, and to the extent required to avoid accelerated taxation and/or tax penalties under Section 409A of the
Code, a Change in Control shall be deemed to have occurred under the Plan with respect to such Award only if a change in the ownership
or effective control of the Company or a change in ownership of a substantial portion of the assets of the Company shall also be deemed
to have occurred under Section 409A of the Code.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Code</U>&rdquo; means
the Internal Revenue Code of 1986, as amended from time to time, or any successor thereto.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Committee</U>&rdquo;
means any committee or subcommittee the Board may appoint to administer the Plan. Subject to the discretion of the Board, the Committee
shall be composed entirely of individuals who meet the qualifications of (i) a &ldquo;non-employee director&rdquo; within the meaning
of Rule&nbsp;16b-3 and (ii) any other qualifications required by any stock exchange on which the Common Shares are traded.&nbsp; If at
any time or to any extent the Board shall not administer the Plan, then the functions of the Administrator specified in the Plan shall
be exercised by the Committee.&nbsp; Except as otherwise provided in the organizational documents of the Company, any action of the Committee
with respect to the administration of the Plan shall be taken by a majority vote at a meeting at which a quorum is duly constituted or
unanimous written consent of the Committee&rsquo;s members.</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Common Shares</U>&rdquo;
means the common shares of the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Company</U>&rdquo;
means ESSA Pharma Inc., a company incorporated under the laws of the Province of British Columbia (or any successor company, except as
the term &ldquo;Company&rdquo; is used in the definition of &ldquo;Change in Control&rdquo; above).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-indent: 1in">&ldquo;<U>Consultant</U>&rdquo; means an individual
or consultant company, other than an employee, a director or an officer of the Company, that:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is
engaged to provide on a <I>bona fide</I> basis, consulting, technical, management or other services to the Company or an Affiliate, other
than services provided in relation to a distribution;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;provides
the services under a written contract between the Company or an Affiliate of the Company and the individual or the consultant company;
and</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the reasonable opinion of the Company, spends or will spend a significant amount of time and attention to the affairs and business of
the Company or an Affiliate.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Disability</U>&rdquo;
has the meaning assigned to such term in the Award Agreement or in any individual employment, service or severance agreement with the
Participant or, if any such agreement does not define &ldquo;Disability,&rdquo; Disability means, with respect to any Participant, that
such Participant, as determined by the Administrator in its sole discretion, is (<U>i</U>) unable to engage in any substantial gainful
activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected
to last for a continuous period of not less than twelve (12) months or (<U>ii</U>) by reason of any medically determinable physical or
mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12)
months, receiving income replacement benefits for a period of not less than three (3) months under an accident and health plan covering
employees of the Participant&rsquo;s employer.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Effective Date</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;20</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Eligible Recipient</U>&rdquo;
means an officer, employee, non-employee director or Consultant of the Company or any Affiliate of the Company who has been selected as
an eligible participant by the Administrator; <U>provided</U>, <U>however</U>, to the extent required to avoid accelerated taxation and/or
tax penalties under Section 409A of the Code, an Eligible Recipient of an Option or a Share Appreciation Right means an employee, non-employee
director or Consultant of the Company or any Affiliate of the Company with respect to whom the Company is an &ldquo;eligible issuer of
service recipient stock&rdquo; within the meaning of Section 409A of the Code.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended from time to time.</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Exercise Price</U>&rdquo;
means, with respect to any Option, the per share price at which a holder of such Option may purchase Common Shares issuable upon the exercise
of such Option.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Fair Market Value</U>&rdquo;
of a Common Share or another security as of a particular date shall mean the fair market value as determined by the Administrator in its
sole discretion; <U>provided</U>, <U>however</U>, (<U>i</U>) if the Common Share or other security is admitted to trading on a national
securities exchange, the fair market value on any date shall be the closing sale price reported on the last preceding date on which there
was a sale of a Common Share or such security on such exchange, or (<U>ii</U>) if the Common Share or other security is then traded in
an over-the-counter market, the fair market value on any date shall be the average of the closing bid and asked prices for a Common Share
or such security in such over-the-counter market for the last preceding date on which there was a sale of a Common Share or such security
in such market.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Free Standing Right</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;8(a)</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Good Reason</U>&rdquo;
has the meaning assigned to such term in the Award Agreement or in any individual employment, service or severance agreement with the
Participant or, if any such agreement does not define &ldquo;Good Reason,&rdquo; Good Reason and any provision of the Plan that refers
to Good Reason shall not be applicable to such Participant.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>ISO</U>&rdquo; means
an Option intended to be and designated as an &ldquo;incentive stock option&rdquo; within the meaning of Section 422 of the Code.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Nonqualified Share
Option</U>&rdquo; means an Option that is not designated as an ISO.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Option</U>&rdquo;
means an option to purchase Common Shares granted pursuant to <U>Section&nbsp;7</U> hereof. The term &ldquo;Option&rdquo; as used in the
Plan includes the terms &ldquo;Nonqualified Share Option&rdquo; and &ldquo;ISO.&rdquo;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Other Share-Based
Award</U>&rdquo; means an Award granted pursuant to <U>Section&nbsp;10</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Participant</U>&rdquo;
means any Eligible Recipient selected by the Administrator, pursuant to the Administrator&rsquo;s authority provided for in <U>Section&nbsp;3</U>
below, to receive grants of Awards, and, upon his or her death, his or her successors, heirs, executors and administrators, as the case
may be.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Person</U>&rdquo;
has the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Plan</U>&rdquo; has
the meaning set forth in <U>Section&nbsp;1</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Restricted Period</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;9(a)</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Related Right</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;8(a)</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Restricted Shares</U>&rdquo;
means Shares granted pursuant to <U>Section&nbsp;9</U> below subject to certain restrictions that lapse at the end of a specified period
or periods.</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Restricted Share
Unit</U>&rdquo; means the right, granted pursuant to <U>Section&nbsp;9</U> below, to receive an amount in cash or Shares (or any combination
thereof) equal to the Fair Market Value of a Common Share subject to certain restrictions that lapse at the end of a specified period
or periods.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Rule 16b-3</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;3(a)</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended from time to time.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Shares</U>&rdquo;
means Common Shares reserved for issuance under the Plan, as adjusted pursuant to the Plan, and any successor (pursuant to a merger, amalgamation,
consolidation or other reorganization) security.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Share Appreciation
Right</U>&rdquo; means the right to receive, upon exercise of the right, the applicable amounts as described in <U>Section&nbsp;8</U>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Share Bonus</U>&rdquo;
means a bonus payable in fully vested Common Shares granted pursuant to <U>Section&nbsp;11</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Subsidiary</U>&rdquo;
means, with respect to any Person, as of any date of determination, any other Person as to which such first Person owns or otherwise controls,
directly or indirectly, more than 50% of the voting shares or other similar interests or a sole general partner interest or managing member
or similar interest of such other Person.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Transfer</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;18</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><B>Section 3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administration</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Plan shall be administered by the Administrator and shall be administered in accordance with the requirements of Rule&nbsp;16b-3 under
the Exchange Act (&ldquo;<U>Rule&nbsp;16b-3</U>&rdquo;), to the extent applicable.&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the terms of the Plan, the Administrator, subject, in the case of any Committee, to any restrictions on the authority delegated to
it by the Board, shall have the power and authority, without limitation:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
select those Eligible Recipients who shall be Participants;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine whether and to what extent Awards are to be granted hereunder to Participants;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine the number of Shares to be covered by each Award granted hereunder;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine the terms and conditions, not inconsistent with the terms of the Plan, of each Award granted hereunder (including, but not limited
to, (<U>i</U>) the restrictions applicable to Restricted Shares or Restricted Share Units and the conditions under which restrictions
applicable to such Restricted Shares or Restricted Share Units shall lapse, (<U>ii</U>) the performance goals and periods applicable to
Awards, (<U>iii</U>) the Exercise Price of each Option and the Base Price of each Share Appreciation Right, (<U>iv</U>) the vesting schedule
applicable to each Award, (<U>v</U>) the number of Shares or amount of cash or other property subject to each Award and (vi) subject to
the requirements of Section 409A of the Code (to the extent applicable), any amendments to the terms and conditions of outstanding Awards,
including, but not limited to, extending the exercise period of such Awards and accelerating the vesting schedule of such Awards);</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine the terms and conditions, not inconsistent with the terms of the Plan, which shall govern all written instruments evidencing
Awards;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine the Fair Market Value in accordance with the terms of the Plan;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine the duration and purpose of leaves of absences which may be granted to a Participant without constituting termination of the
Participant&rsquo;s employment or service for purposes of Awards;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
adopt, alter and repeal such administrative rules, guidelines and practices governing the Plan as it shall from time to time deem advisable;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
prescribe, amend and rescind rules and regulations relating to sub-plans established for the purpose of satisfying applicable foreign
laws or qualifying for favorable tax treatment under applicable foreign laws, which rules and regulations may be set forth in an appendix
or appendices to the Plan; and</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(10)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
construe and interpret the terms and provisions of the Plan and any Award issued under the Plan (and any Award Agreement relating thereto),
and to otherwise supervise the administration of the Plan and to exercise all powers and authorities either specifically granted under
the Plan or necessary and advisable in the administration of the Plan.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to <U>Section&nbsp;5</U>, neither the Board nor the Committee shall have the authority to reprice or cancel and regrant any Award at a
lower exercise, base or purchase price or cancel any Award with an exercise, base or purchase price in exchange for cash, property or
other Awards without first obtaining the approval of the Company&rsquo;s shareholders to the extent required by the rules of any stock
exchange on which the Common Shares are traded or other applicable law.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
decisions made by the Administrator pursuant to the provisions of the Plan shall be final, conclusive and binding on all Persons, including
the Company and the Participants. No member of the Board or the Committee, nor any officer or employee of the Company or any Subsidiary
thereof acting on behalf of the Board or the Committee, shall be personally liable for any action, omission, determination, or interpretation
taken or made in good faith with respect to the Plan, and all members of the Board or the Committee and each and any officer or employee
of the Company and of any Subsidiary thereof acting on their behalf shall, to the maximum extent permitted by law, be fully indemnified
and protected by the Company in respect of any such action, omission, determination or interpretation.</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Administrator in its discretion may accelerate the vesting of or waive restrictions on Awards in whole or in part at any time for any
reason.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Administrator may, in its sole discretion, delegate its authority, in whole or in part, under this <U>Section&nbsp;3</U> (including, but
not limited to, its authority to grant Awards under the Plan, other than its authority to grant Awards under the Plan to any Participant
who is subject to reporting under Section 16 of the Exchange Act) to one or more officers of the Company, subject to the requirements
of applicable law or any stock exchange on which the Common Shares are traded.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><B>Section 4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Reserved for Issuance;
Certain Limitations</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
maximum number of Common Shares reserved for issuance under the Plan shall be 8,410,907 (subject to adjustment as provided by <U>Section&nbsp;5</U>).
All of the Common Shares reserved for issuance under the Plan may be made subject to ISOs. From and after February 25, 2021, no additional
awards shall be granted under the Company&rsquo;s Amended Option Plan or Share Unit Plan.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
issued under the Plan may, in whole or in part, be authorized but unissued Shares or Shares that shall have been or may be reacquired
by the Company in the open market, in private transactions or otherwise. If any Shares subject to an Award are forfeited, cancelled, exchanged
or surrendered or if an Award otherwise terminates or expires without a distribution of Shares to the Participant, the Shares with respect
to such Award shall, to the extent of any such forfeiture, cancellation, exchange, surrender, termination or expiration, again be available
for Awards under the Plan. Shares that are exchanged by a Participant or withheld by the Company as full or partial payment in connection
with the exercise of any Option or Share Appreciation Right under the Plan or the payment of any purchase price with respect to other
Awards under the Plan, as well as any Shares exchanged by a Participant or withheld by the Company or any Subsidiary to satisfy the tax
withholding obligations related to any Award under the Plan, shall not again be available for subsequent Awards under the Plan. With respect
to any Share Appreciation Right that is settled by the delivery of a net number of Common Shares, the gross number of Common Shares delivered
in settlement of such Share Appreciation Right shall not be available for subsequent Awards under the Plan. Upon the exercise of any Award
granted in tandem with any other Awards, such related Awards shall be cancelled to the extent of the number of Shares as to which the
Award is exercised and, notwithstanding the foregoing, such number of shares shall no longer be available for Awards under the Plan. In
addition, (<U>i</U>) to the extent an Award is denominated in Common Shares, but paid or settled in cash, the number of Common Shares
with respect to which such payment or settlement is made shall again be available for grants of Awards pursuant to the Plan and (<U>ii</U>)
Common Shares underlying Awards that can only be settled in cash shall not be counted against the aggregate number of Common Shares available
for Awards under the Plan.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to Section 3(e), any Awards that settle in Common Shares (other than such Awards representing a maximum of five percent (5%) of the Common
Shares reserved for issuance under the Plan, as adjusted pursuant to Section&nbsp;5) shall be granted subject to a minimum time-vesting
period of at least twelve (12) months, such that no such Awards shall vest prior to the first anniversary of the applicable grant date.</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><B>Section 5. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equitable Adjustments</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of any Change in Capitalization (including a Change in Control), an equitable substitution or proportionate adjustment shall
be made, in each case by the Administrator, in its sole discretion, in (<U>i</U>) the aggregate number of Common Shares reserved for issuance
under the Plan and the maximum number of Common Shares or cash that may be subject to Awards granted to any Participant in any calendar
year, (<U>ii</U>) the kind and number of securities subject to, and the Exercise Price or Base Price of, any outstanding Options and Share
Appreciation Rights granted under the Plan, (<U>iii</U>) the kind, number and purchase price of Common Shares, or the amount of cash or
amount or type of other property, subject to outstanding Restricted Shares, Restricted Share Units, Share Bonuses and Other Share-Based
Awards granted under the Plan, or (<U>iv</U>) the performance goals and performance periods applicable to any Awards granted under the
Plan; <U>provided</U>, <U>however</U>, that any fractional shares resulting from the adjustment shall be eliminated unless otherwise determined
by the Administrator. Such other equitable substitutions or adjustments shall be made as may be determined by the Administrator, in its
sole discretion.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting the generality of the foregoing, in connection with a Change in Capitalization (including a Change in Control), the Administrator
may provide, in its sole discretion, but subject in all events to the requirements of Section 409A of the Code, for the cancellation of
any outstanding Award in exchange for payment in cash or other property having an aggregate Fair Market Value equal to the Fair Market
Value of the Common Shares, cash or other property covered by such Award, reduced by the aggregate Exercise Price or Base Price thereof,
if any; <U>provided</U>, <U>however</U>, that if the Exercise Price or Base Price of any outstanding Award is equal to or greater than
the Fair Market Value of the Common Shares, cash or other property covered by such Award, the Administrator may cancel such Award without
the payment of any consideration to the Participant.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
determinations made by the Administrator or the Board, as applicable, pursuant to this <U>Section&nbsp;5</U> shall be final, binding and
conclusive.</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 0in">Section 6. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eligibility.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify">The Participants under the Plan shall be selected
from time to time by the Administrator, in its sole discretion, from those individuals that qualify as Eligible Recipients.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><B>Section 7. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>General</U></FONT>.
Each Participant who is granted an Option shall enter into an Award Agreement with the Company, containing such terms and conditions as
the Administrator shall determine, in its sole discretion, which Award Agreement shall set forth, among other things, the Exercise Price
of the Option, the term of the Option and provisions regarding exercisability of the Option, and whether the Option is intended to be
an ISO or a Nonqualified Share Option (and in the event the Award Agreement has no such designation, the Option shall be a Nonqualified
Share Option). The provisions of each Option need not be the same with respect to each Participant. More than one Option may be granted
to the same Participant and be outstanding concurrently hereunder. Options granted under the Plan shall be subject to the terms and conditions
set forth in this <U>Section&nbsp;7</U> and shall contain such additional terms and conditions, not inconsistent with the terms of the
Plan, as the Administrator shall deem desirable and set forth in the applicable Award Agreement.</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exercise
Price</U></FONT>. The Exercise Price of Shares purchasable under an Option shall be determined by the Administrator in its sole discretion
at the time of grant, but in no event shall the Exercise Price of an Option be less than one hundred percent (100%) of the Fair Market
Value of the related Common Shares on the date of grant.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Option
Term</U></FONT>. The maximum term of each Option shall be fixed by the Administrator, but no Option shall be exercisable more than ten
(10) years after the date such Option is granted. Each Option&rsquo;s term is subject to earlier expiration pursuant to the applicable
provisions in the Plan and the Award Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exercisability</U></FONT>.
Each Option shall be exercisable at such time or times and subject to such terms and conditions, including the attainment of pre-established
performance goals, as shall be determined by the Administrator in the applicable Award Agreement. The Administrator may also provide that
any Option shall be exercisable only in installments, and the Administrator may waive such installment exercise provisions at any time,
in whole or in part, based on such factors as the Administrator may determine in its sole discretion. Notwithstanding anything to the
contrary contained herein, an Option may not be exercised for a fraction of a share.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Method
of Exercise</U></FONT>. Options may be exercised in whole or in part by giving written notice of exercise to the Company specifying the
number of whole Shares to be purchased, accompanied by payment in full of the aggregate Exercise Price of the Shares so purchased in cash
or its equivalent, as determined by the Administrator.&nbsp; As determined by the Administrator, in its sole discretion, with respect
to any Option or category of Options, payment in whole or in part may also be made (i)&nbsp;by means of consideration received under any
cashless exercise procedure approved by the Administrator (including the withholding of Shares otherwise issuable upon exercise), (ii)&nbsp;in
the form of unrestricted Shares already owned by the Participant which have a Fair Market Value on the date of surrender equal to the
aggregate exercise price of the Shares as to which such Option shall be exercised, (iii)&nbsp;any other form of consideration approved
by the Administrator and permitted by applicable law or (iv)&nbsp;any combination of the foregoing.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>ISOs</U>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-variant: normal; font-weight: normal; text-transform: none"><I>ISOs</I></FONT>.
The terms and conditions of ISOs granted hereunder shall be subject to the provisions of Section 422 of the Code and the terms, conditions,
limitations and administrative procedures established by the Administrator from time to time in accordance with the Plan. At the discretion
of the Administrator, ISOs may be granted only to an employee of the Company, its &ldquo;parent corporation&rdquo; (as such term is defined
in Section 424(e) of the Code) or a Subsidiary of the Company. All of the Common Shares reserved for issuance under the Plan pursuant
to Section&nbsp;4(a) hereof (subject to adjustment as provided in Section&nbsp;5 hereof) may be granted as ISOs.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-variant: normal; font-weight: normal; text-transform: none"><I>ISO
Grants to 10% Shareholders</I></FONT>. Notwithstanding anything to the contrary in the Plan, if an ISO is granted to a Participant who
owns shares representing more than ten percent (10%) of the voting power of all classes of shares of the Company, its &ldquo;parent corporation&rdquo;
(as such term is defined in Section 424(e) of the Code) or a Subsidiary of the Company, the term of the ISO shall not exceed five (5)
years from the time of grant of such ISO and the Exercise Price shall be at least one hundred and ten percent (110%) of the Fair Market
Value of the Shares on the date of grant.</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-variant: normal; font-weight: normal; text-transform: none"><I>$100,000
Per Year Limitation For ISOs</I></FONT>. To the extent the aggregate Fair Market Value (determined on the date of grant) of the Shares
for which ISOs are exercisable for the first time by any Participant during any calendar year (under all plans of the Company) exceeds
$100,000, such excess ISOs shall be treated as Nonqualified Share Options.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-variant: normal; font-weight: normal; text-transform: none"><I>Disqualifying
Dispositions</I></FONT>. Each Participant awarded an ISO under the Plan shall notify the Company in writing immediately after the date
the Participant makes a &ldquo;disqualifying disposition&rdquo; of any Share acquired pursuant to the exercise of such ISO. A &ldquo;disqualifying
disposition&rdquo; is any disposition (including any sale) of such Shares before the later of (<U>i</U>) two years after the date of grant
of the ISO and (<U>ii</U>) one year after the date the Participant acquired the Shares by exercising the ISO. The Company may, if determined
by the Administrator and in accordance with procedures established by it, retain possession of any Shares acquired pursuant to the exercise
of an ISO as agent for the applicable Participant until the end of the period described in the preceding sentence, subject to complying
with any instructions from such Participant as to the sale of such Shares.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Rights
as Shareholder</U></FONT>. A Participant shall have no rights to dividends, dividend equivalents or distributions, or any other rights
of a shareholder with respect to the Shares subject to an Option, until the Participant has given written notice of the exercise thereof,
has paid in full for such Shares and has satisfied the requirements of <U>Section&nbsp;18</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Termination
of Employment or Service</U></FONT>. In the event of the termination of employment or service with the Company and all Affiliates thereof
of a Participant who has been granted one or more Options, such Options shall be exercisable at such time or times and subject to such
terms and conditions as set forth in the Award Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Other
Change in Employment or Service Status</U></FONT>. An Option shall be affected, both with regard to vesting schedule and termination,
by leaves of absence, changes from full-time to part-time employment, partial disability or other changes in the employment or service
status of an Participant, in the discretion of the Administrator.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 8. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share Appreciation Rights</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>General</U></FONT>.
Share Appreciation Rights may be granted either alone (&ldquo;<U>Free Standing Rights</U>&rdquo;) or in conjunction with all or part of
any Option granted under the Plan (&ldquo;<U>Related Rights</U>&rdquo;). Related Rights may be granted either at or after the time of
the grant of such Option. The Administrator shall determine the Eligible Recipients to whom, and the time or times at which, grants of
Share Appreciation Rights shall be made, the number of Shares to be awarded, the Base Price, and all other conditions of Share Appreciation
Rights. Notwithstanding the foregoing, no Related Right may be granted for more Shares than are subject to the Option to which it relates.
The provisions of Share Appreciation Rights need not be the same with respect to each Participant. Share Appreciation Rights granted under
the Plan shall be subject to the following terms and conditions set forth in this <U>Section&nbsp;8</U> and shall contain such additional
terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable, as set forth in the applicable
Award Agreement.</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Base
Price</U></FONT>. Each Share Appreciation Right shall be granted with a base price that is not less than one hundred percent (100%) of
the Fair Market Value of the related Common Shares on the date of grant (such amount, the &ldquo;<U>Base Price</U>&rdquo;).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Rights
as Shareholder</U></FONT>. A Participant shall have no rights to dividends, dividend equivalents or distributions, or any other rights
of a shareholder with respect to the Common Shares, if any, subject to a Share Appreciation Right, until the Participant has given written
notice of the exercise thereof and has satisfied the requirements of <U>Section&nbsp;18</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exercisability</U></FONT>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share
Appreciation Rights that are Free Standing Rights shall be exercisable at such time or times and subject to such terms and conditions
as shall be determined by the Administrator in the applicable Award Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share
Appreciation Rights that are Related Rights shall be exercisable only at such time or times and to the extent that the Options to which
they relate shall be exercisable in accordance with the provisions of <U>Sections&nbsp;7</U> and&nbsp;<U>8</U> hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Consideration
Upon Exercise</U></FONT>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the exercise of a Free Standing Right, the Participant shall be entitled to receive up to, but not more than, that number of Shares equal
in value to (i) the excess of the Fair Market Value of a Common Share as of the date of exercise over the Base Price per share specified
in the Free Standing Right, multiplied by (ii) the number of Shares in respect of which the Free Standing Right is being exercised.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
Related Right may be exercised by a Participant by surrendering the applicable portion of the related Option. Upon such exercise and surrender,
the Participant shall be entitled to receive up to, but not more than, that number of Shares equal in value to (i) the excess of the Fair
Market Value of a Common Share as of the date of exercise over the Exercise Price specified in the related Option, multiplied by (ii)
the number of Shares in respect of which the Related Right is being exercised. Options which have been so surrendered, in whole or in
part, shall no longer be exercisable to the extent the Related Rights have been so exercised.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, the Administrator may determine to settle the exercise of a Share Appreciation Right in cash (or in any combination of
Shares and cash).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Termination
of Employment or Service</U></FONT>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of the termination of employment or service with the Company and all Affiliates thereof of a Participant who has been granted
one or more Free Standing Rights, such rights shall be exercisable at such time or times and subject to such terms and conditions as set
forth in the Award Agreement.</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of the termination of employment or service with the Company and all Affiliates thereof of a Participant who has been granted
one or more Related Rights, such rights shall be exercisable at such time or times and subject to such terms and conditions as set forth
in the related Options.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Other
Change in Employment or Service Status</U></FONT>. Stock Appreciation Rights shall be affected, both with regard to vesting schedule and
termination, by leaves of absence, changes from full-time to part-time employment, partial disability or other changes in the employment
or service status of an Participant, in the discretion of the Administrator.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Term</U></FONT>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term of each Free Standing Right shall be fixed by the Administrator, but no Free Standing Right shall be exercisable more than ten (10)
years after the date such right is granted.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term of each Related Right shall be the term of the Option to which it relates, but no Related Right shall be exercisable more than ten
(10) years after the date such right is granted.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><B>Section 9. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Shares and
Restricted Share Units</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>General</U></FONT>.
Restricted Shares and Restricted Share Units may be issued either alone or in addition to other awards granted under the Plan. The Administrator
shall determine the Eligible Recipients to whom, and the time or times at which, Restricted Shares or Restricted Share Units shall be
made; the number of Shares to be awarded; the price, if any, to be paid by the Participant for the acquisition of Restricted Shares or
Restricted Share Units; the period of time prior to which Restricted Shares or Restricted Share Units become vested and free of restrictions
on Transfer (the &ldquo;<U>Restricted Period</U>&rdquo;); the performance objectives (if any); and all other conditions of the Restricted
Shares and Restricted Share Units. If the restrictions, performance objectives and/or conditions established by the Administrator are
not attained, a Participant shall forfeit his or her Restricted Shares or Restricted Share Units, in accordance with the terms of the
grant. The provisions of Restricted Shares or Restricted Share Units need not be the same with respect to each Participant.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Awards
and Certificates</U></FONT>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided below in <U>Section&nbsp;9(c)</U>, (i) each Participant who is granted an Award of Restricted Shares may, in the
Company&rsquo;s sole discretion, be issued a share certificate in respect of such Restricted Shares; and (ii) any such certificate so
issued shall be registered in the name of the Participant, and shall bear an appropriate legend referring to the terms, conditions, and
restrictions applicable to any such Award. The Company may require that the share certificates, if any, evidencing Restricted Shares be
held in the custody of the Company until the restrictions thereon shall have lapsed, and that, as a condition of any award of Restricted
Shares, the Participant shall have delivered a share transfer form, endorsed in blank, relating to the Shares covered by such award. Certificates
for unrestricted Common Shares may, in the Company&rsquo;s sole discretion, be delivered to the Participant only after the Restricted
Period has expired without forfeiture in respect of such Restricted Shares.</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to an Award of Restricted Share Units to be settled in Shares, at the expiration of the Restricted Period, share certificates
in respect of the Common Shares underlying such Restricted Share Units may, in the Company&rsquo;s sole discretion, be delivered to the
Participant, or his legal representative, in a number equal to the number of Common Shares underlying the Restricted Share Units.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything in the Plan to the contrary, any Restricted Shares or Restricted Share Units to be settled in Shares (at the expiration of the
Restricted Period) may, in the Company&rsquo;s sole discretion, be issued in uncertificated form.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
notwithstanding anything in the Plan to the contrary, with respect to Restricted Share Units, at the expiration of the Restricted Period,
Shares or cash, as applicable, shall promptly be issued or paid to the Participant, unless otherwise deferred in accordance with procedures
established by the Company in accordance with Section 409A of the Code, and such issuance or payment shall in any event be made no later
than March 15<SUP>th</SUP> of the calendar year following the year of vesting or within such other period as is required to avoid accelerated
taxation and/or tax penalties under Section 409A of the Code.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Restrictions
and Conditions</U></FONT>. The Restricted Shares and Restricted Share Units granted pursuant to this <U>Section&nbsp;9</U> shall be subject
to the following restrictions and conditions and any additional restrictions or conditions as determined by the Administrator at the time
of grant or, subject to Section 409A of the Code where applicable, thereafter:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Administrator may, in its sole discretion, provide in the Award Agreement for the lapse of restrictions in installments and may accelerate
or waive such restrictions in whole or in part based on such factors and such circumstances as the Administrator may determine, in its
sole discretion, including, but not limited to, the attainment of certain performance-related goals, the Participant&rsquo;s termination
of employment or service as an officer, director or Consultant to the Company or any Affiliate thereof, or the Participant&rsquo;s death
or Disability. Notwithstanding the foregoing, upon a Change in Control, the outstanding Awards shall be subject to <U>Section&nbsp;15</U>
hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as provided in the applicable Award Agreement, the Participant shall generally have the rights of a shareholder of the Company with respect
to Restricted Shares during the Restricted Period, including the right to vote such shares and to receive any dividends declared with
respect to such shares; <U>provided</U>, <U>however</U>, that, except as provided in the applicable Award Agreement, any dividends declared
during the Restricted Period with respect to such shares shall only become payable if (and to the extent) the underlying Restricted Shares
vest. Except as provided in the applicable Award Agreement, the Participant shall generally not have the rights of a shareholder with
respect to Common Shares subject to Restricted Share Units during the Restricted Period; <U>provided</U>, <U>however</U>, that, subject
to Section 409A of the Code, an amount equal to any dividends declared during the Restricted Period with respect to the number of Common
Shares covered by Restricted Share Units may, to the extent set forth in an Award Agreement, be provided to the Participant at the time
(and to the extent) that Common Shares in respect of the related Restricted Share Units are delivered to the Participant.</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Termination
of Employment or Service</U></FONT>. The rights of Participants granted Restricted Shares or Restricted Share Units upon termination of
employment or service with the Company and all Affiliates thereof for any reason during the Restricted Period shall be set forth in the
Award Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Form
of Settlement</U>. The Administrator reserves the right in its sole discretion to provide (either at or after the grant thereof) that
any Restricted Share Unit represents the right to receive the amount of cash per unit that is determined by the Administrator in connection
with the Award.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 10. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Share-Based Awards</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">Other forms of Awards valued
in whole or in part by reference to, or otherwise based on, Common Shares, including but not limited to dividend equivalents, may be granted
either alone or in addition to other Awards (other than in connection with Options or Share Appreciation Rights) under the Plan. Any dividend
or dividend equivalent awarded hereunder shall be subject to the same restrictions, conditions and risks of forfeiture as the underlying
Award, and shall only become payable if (and to the extent) the underlying Award vests. Subject to the provisions of the Plan, the Administrator
shall have sole and complete authority to determine the Eligible Recipients to whom and the time or times at which such Other Share-Based
Awards shall be granted, the number of Common Shares to be granted pursuant to such Other Share-Based Awards, or the manner in which such
Other Share-Based Awards shall be settled (<I>e.g.</I>, in Common Shares, cash or other property), or the conditions to the vesting and/or
payment or settlement of such Other Share-Based Awards (which may include, but not be limited to, achievement of performance criteria)
and all other terms and conditions of such Other Share-Based Awards.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 11. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share Bonuses</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">In the event that the Administrator
grants a Share Bonus, the Shares constituting such Share Bonus shall, as determined by the Administrator, be evidenced in uncertificated
form or by a book entry record or a certificate issued in the name of the Participant to whom such grant was made and delivered to such
Participant as soon as practicable after the date on which such Share Bonus is payable.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 12. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash Awards</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">The Administrator may grant
Awards that are payable solely in cash, as deemed by the Administrator to be consistent with the purposes of the Plan, and such Cash Awards
shall be subject to the terms, conditions, restrictions and limitations determined by the Administrator, in its sole discretion, from
time to time. Cash Awards may be granted with value and payment contingent upon the achievement of performance criteria.</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><I>&nbsp;</I></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 13. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in Control Provisions</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">Except as otherwise provided
in an applicable Award Agreement, in the event of a Change in Control:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to each outstanding Award that is assumed or substituted in connection with a Change in Control, in the event of a termination
of a Participant&rsquo;s service to the Company without Cause during the 24-month period following such Change in Control, on the date
of such termination (<U>i</U>) such Award shall become fully vested and, if applicable, exercisable, (<U>ii</U>) the restrictions, payment
conditions, and forfeiture conditions applicable to any such Award granted shall lapse, and (<U>iii</U>) any performance conditions imposed
with respect to Awards shall be deemed to be fully achieved at target levels.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to each outstanding Award that is not assumed or substituted in connection with a Change in Control, immediately upon the occurrence
of the Change in Control, (<U>i</U>) such Award shall become fully vested and, if applicable, exercisable, (<U>ii</U>) the restrictions,
payment conditions, and forfeiture conditions applicable to any such Award granted shall lapse, and (<U>iii</U>) any performance conditions
imposed with respect to Awards shall be deemed to be fully achieved at target levels.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this <U>Section&nbsp;13</U>, an outstanding Award shall be considered to be assumed or substituted for if, following the Change
in Control, the Award remains subject to terms and conditions that are no less favorable in any respect than those that were applicable
to the Award immediately prior to the Change in Control except that, if the Award related to Shares, the Award may instead confer the
right to receive common stock of the acquiring entity (or such other security as may be determined by the Administrator, in its sole discretion,
pursuant to <U>Section&nbsp;5</U> hereof) with an aggregate Fair Market Value that is at least equal to the aggregate Fair Market Value
of the Common Shares subject to the Award immediately prior to the Change in Control.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify">Notwithstanding any other provision of the Plan,
(<U>i</U>) in the event of a Change in Control, except as would otherwise result in adverse tax consequences under Section 409A of the
Code, the Board may, in its sole discretion, provide that each Award shall, immediately upon the occurrence of a Change in Control, be
cancelled in exchange for a payment in cash or securities in an amount equal to (<U>x</U>) the excess of the consideration paid per Share
in the Change in Control over the exercise or purchase price (if any) per Share subject to the Award multiplied by (<U>y</U>) the number
of Shares granted under the Award and (<U>ii</U>) with respect to any Award that constitutes a deferral of compensation subject to Section
409A of the Code, in the event of a Change in Control that does not constitute a change in the ownership or effective control of the Company
or in the ownership of a substantial portion of the assets of the Company under Section 409A(a)(2)(A)(v) of the Code and regulations thereunder,
such Award shall be settled in accordance with its original terms or at such earlier time as permitted by Section 409A of the Code.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 14. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment and Termination</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">The Board may amend, alter
or terminate the Plan, but no amendment, alteration, or termination shall be made that would materially impair the rights of a Participant
under any Award previously granted without such Participant&rsquo;s consent. Unless the Board determines otherwise, the Board shall obtain
approval of the Company&rsquo;s shareholders for any amendment to the Plan that would require such approval in order to satisfy any rules
of any stock exchange on which the Common Shares are traded or other applicable law. The Administrator may amend the terms of any Award
previously granted, prospectively or retroactively, but, subject to <U>Section&nbsp;5</U> hereof and the immediately preceding sentence,
no such amendment shall materially impair the rights of any Participant without his or her consent.</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 15. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unfunded Status of Plan</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">The Plan is intended to constitute
an &ldquo;unfunded&rdquo; plan for incentive compensation. With respect to any payments not yet made to a Participant by the Company,
nothing contained herein shall give any such Participant any rights that are greater than those of a general creditor of the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 16. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Withholding Taxes</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">Each Participant shall, no
later than the date as of which the value of an Award first becomes includible in the gross income of such Participant for purposes of
applicable taxes, pay to the Company, or make arrangements satisfactory to the Company regarding payment of, an amount in respect of such
taxes up to the maximum statutory rates in the Participant&rsquo;s applicable jurisdiction with respect to the Award, as determined by
the Company. The obligations of the Company under the Plan shall be conditional on the making of such payments or arrangements, and the
Company shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to such
Participant. Whenever cash is to be paid pursuant to an Award, the Company shall have the right to deduct therefrom an amount sufficient
to satisfy any applicable withholding tax requirements related thereto as determined by the Company. Whenever Shares or property other
than cash are to be delivered pursuant to an Award, the Company shall have the right to require the Participant to remit to the Company
in cash an amount sufficient to satisfy any related taxes to be withheld and applied to the tax obligations as determined by the Company;
<U>provided</U>, that, with the approval of the Administrator, a Participant may satisfy the foregoing requirement by either (<U>i</U>)
electing to have the Company withhold from the delivery of Shares or other property, as applicable, or (<U>ii</U>) by delivering already
owned unrestricted Common Shares, in each case, having a value not exceeding the applicable taxes to be withheld and applied to the tax
obligations as determined by the Company. Such already owned and unrestricted Common Shares shall be valued at their Fair Market Value
on the date on which the amount of tax to be withheld is determined and any fractional share amounts resulting therefrom shall be settled
in cash. Such an election may be made with respect to all or any portion of the Shares to be delivered pursuant to an Award. The Company
may also use any other method of obtaining the necessary payment or proceeds, as permitted by law, to satisfy its withholding obligation
with respect to any Award as determined by the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 17. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer of Awards</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">Until such time as the Awards
are fully vested and/or exercisable in accordance with the Plan or an Award Agreement, no purported sale, assignment, mortgage, hypothecation,
transfer, charge, pledge, encumbrance, gift, transfer in trust (voting or other) or other disposition of, or creation of a security interest
in or lien on, any Award or any agreement or commitment to do any of the foregoing (each, a &ldquo;<U>Transfer</U>&rdquo;) by any holder
thereof in violation of the provisions of the Plan or an Award Agreement will be valid, except with the prior written consent of the Administrator,
which consent may be granted or withheld in the sole discretion of the Administrator. Any purported Transfer of an Award or any economic
benefit or interest therein in violation of the Plan or an Award Agreement shall be null and void <I>ab initio</I>, and shall not create
any obligation or liability of the Company, and any Person purportedly acquiring any Award or any economic benefit or interest therein
transferred in violation of the Plan or an Award Agreement shall not be entitled to be recognized as a holder of any Common Shares or
other property underlying such Award. Unless otherwise determined by the Administrator, an Option may be exercised, during the lifetime
of the Participant, only by the Participant or, during any period during which the Participant is under a legal disability, by the Participant&rsquo;s
guardian or legal representative.</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 18. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Continued Employment or Service</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">Neither the adoption of the
Plan nor the grant of an Award hereunder shall confer upon any Eligible Recipient any right to continued employment or service with the
Company or any Affiliate thereof, as the case may be, nor shall it interfere in any way with the right of the Company or any Affiliate
thereof to terminate the employment or service of any of its Eligible Recipients at any time.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 19. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective Date</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">The Plan became effective upon
adoption by the Board on January 14, 2021 (the &ldquo;<U>Effective Date</U>&rdquo;), subject to requisite approval of shareholders of
the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 20. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term of Plan</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">No Award shall be granted pursuant
to the Plan on or after the tenth anniversary of the Effective Date, but Awards theretofore granted may extend beyond that date.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 21. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities Matters and Regulations</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything herein to the contrary, the obligation of the Company to sell or deliver Common Shares with respect to any Award granted under
the Plan shall be subject to all applicable laws, rules and regulations, including all applicable federal and state securities laws of
the United States and the securities laws of Canada, and the obtaining of all such approvals by governmental agencies as may be deemed
necessary or appropriate by the Administrator. The Administrator may require, as a condition of the issuance and delivery of certificates
evidencing Common Shares pursuant to the terms hereof, that the recipient of such shares make such agreements and representations, and
that such certificates bear such legends, as the Administrator, in its sole discretion, deems necessary or advisable.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Award is subject to the requirement that, if at any time the Administrator determines that the listing, registration or qualification
of Common Shares issuable pursuant to the Plan is required by any securities exchange or under any state or federal law, or the consent
or approval of any governmental regulatory body is necessary or desirable as a condition of, or in connection with, the grant of an Award
or the issuance of Common Shares, no such Award shall be granted or payment made or Common Shares issued, in whole or in part, unless
listing, registration, qualification, consent or approval has been effected or obtained free of any conditions not acceptable to the Administrator.</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that the disposition of Common Shares acquired pursuant to the Plan is not covered by a then current registration statement
under the Securities Act, and is not otherwise exempt from such registration, such Common Shares shall be restricted against transfer
to the extent required by the Securities Act and the regulations thereunder, and the Administrator may require a Participant receiving
Common Shares pursuant to the Plan, as a condition precedent to receipt of such Common Shares, to represent to the Company in writing
that the Common Shares acquired by such Participant are being acquired for investment purposes only and not with a view to distribution.</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-indent: 0in">Section 22. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notification of Election
Under Section 83(b) of the Code.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">If any Participant shall, in
connection with the acquisition of Common Shares under the Plan, make the election permitted under Section 83(b) of the Code, such Participant
shall notify the Company of such election within ten (10) days after filing notice of the election with the Internal Revenue Service.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 23. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Fractional Shares</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">No fractional Shares shall
be issued or delivered pursuant to the Plan. <FONT STYLE="font-family: TimesNewRoman">The Administrator shall determine whether cash,
other Awards, or other property shall be issued or paid in lieu of such fractional Shares, or whether such fractional Shares or any rights
thereto shall be forfeited or otherwise eliminated</FONT>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 24. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficiary</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">A Participant may file with
the Administrator a written designation of a beneficiary on such form as may be prescribed by the Administrator and may, from time to
time, amend or revoke such designation. If no designated beneficiary survives the Participant, the executor or administrator of the Participant&rsquo;s
estate shall be deemed to be the Participant&rsquo;s beneficiary.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 25. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paperless Administration</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">In the event that the Company
establishes, for itself or using the services of a third party, an automated system for the documentation, granting or exercise of Awards,
such as a system using an internet website or interactive voice response, then the paperless documentation, granting or exercise of Awards
by a Participant may be permitted through the use of such an automated system.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 26. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">If any provision of the Plan
is held to be invalid or unenforceable, the other provisions of the Plan shall not be affected but shall be applied as if the invalid
or unenforceable provision had not been included in the Plan.</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 27. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clawback</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: TimesNewRoman">Each
Award shall be subject to any applicable recoupment policy maintained by the Company or any of its Affiliates as in effect from time to
time.</FONT> Notwithstanding any other provisions in this Plan, any Award which is subject to recovery under any law, government regulation,
stock exchange listing requirement or policy of the Company or its Affiliates, will be subject to such deductions and clawback as may
be required to be made pursuant to such law, government regulation, stock exchange listing requirement or policy.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 28. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 409A of the Code</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">The Plan as well as payments
and benefits under the Plan are intended to be exempt from, or to the extent subject thereto, to comply with Section 409A of the Code,
and, accordingly, to the maximum extent permitted, the Plan shall be interpreted in accordance therewith. Notwithstanding anything contained
herein to the contrary, to the extent required in order to avoid accelerated taxation and/or tax penalties under Section 409A of the Code,
the Participant shall not be considered to have terminated employment or service with the Company for purposes of the Plan and no payment
shall be due to the Participant under the Plan or any Award until the Participant would be considered to have incurred a &ldquo;separation
from service&rdquo; from the Company and its Affiliates within the meaning of Section 409A of the Code. Any payments described in the
Plan that are due within the &ldquo;short term deferral period&rdquo; as defined in Section 409A of the Code shall not be treated as deferred
compensation unless applicable law requires otherwise. Notwithstanding anything to the contrary in the Plan, to the extent that any Awards
(or any other amounts payable under any plan, program or arrangement of the Company or any of its Affiliates) are payable upon a separation
from service and such payment would result in the imposition of any individual tax and penalty interest charges imposed under Section
409A of the Code, the settlement and payment of such awards (or other amounts) shall instead be made on the first business day after the
date that is six (6) months following such separation from service (or death, if earlier). Each amount to be paid or benefit to be provided
under this Plan shall be construed as a separate identified payment for purposes of Section 409A of the Code. The Company makes no representation
that any or all of the payments or benefits described in this Plan will be exempt from or comply with Section 409A of the Code and makes
no undertaking to preclude Section 409A of the Code from applying to any such payment. The Participant shall be solely responsible for
the payment of any taxes and penalties incurred under Section&nbsp;409A.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 29. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing Law</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">The Plan and all determinations
made and actions taken pursuant thereto shall be governed by the laws of the Province of British Columbia, without giving effect to the
conflict of laws principles thereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 30. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Titles and Headings</B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 1in">The titles and headings of
the sections in the Plan are for convenience of reference only and, in the event of any conflict, the text of the Plan, rather than such
titles or headings, shall control.</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Section 31. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Successors</B>.</P>

<P STYLE="font: 12pt TimesNewRoman; margin: 12pt 0; text-align: justify; text-indent: 1in">The obligations of the Company under the Plan
shall be binding upon any successor corporation or organization resulting from the merger, consolidation or other reorganization of the
Company, or upon any successor corporation or organization succeeding to substantially all of the assets and business of the Company.</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in">Section 32. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Relationship to other
Benefits<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 12pt TimesNewRoman; margin: 12pt 0; text-align: justify; text-indent: 1in">No payment pursuant to the Plan shall be taken
into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare, or other benefit
plan of the Company or any Affiliate except to the extent otherwise expressly provided in writing in such other plan or an agreement thereunder.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR>
</TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>epi-20220309.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +qkps7xRiXgen8uPY3xcWaeCKaPtz5h0SZkht2hxfZk6Ty8oQqBmBirx9Wzm0T0O -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:EPI="http://essapharmaceuticals.com/20220309" elementFormDefault="qualified" targetNamespace="http://essapharmaceuticals.com/20220309">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://essapharmaceuticals.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="epi-20220309_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="epi-20220309_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>epi-20220309_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>epi-20220309_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://essapharmaceuticals.com/role/Cover" xlink:href="epi-20220309.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://essapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139863758288968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  09,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ESSA Pharma Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001633932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2569713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Suite 720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">999 West Broadway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vancouver<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">BC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V5Z 1K5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">331-0962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EPIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>essa8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="epi-20220309.xsd" xlink:type="simple"/>
    <context id="From2022-03-09to2022-03-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <startDate>2022-03-09</startDate>
            <endDate>2022-03-09</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-03-09to2022-03-09">0001633932</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-03-09to2022-03-09">false</dei:AmendmentFlag>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-03-09to2022-03-09" id="xdx2ixbrl0012">A1</dei:EntityIncorporationStateCountryCode>
    <dei:DocumentType contextRef="From2022-03-09to2022-03-09">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-03-09to2022-03-09">2022-03-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-03-09to2022-03-09">ESSA Pharma Inc.</dei:EntityRegistrantName>
    <dei:EntityFileNumber contextRef="From2022-03-09to2022-03-09">001-37410</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-03-09to2022-03-09">47-2569713</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-03-09to2022-03-09">Suite 720</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-03-09to2022-03-09">999 West Broadway</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-03-09to2022-03-09">Vancouver</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-03-09to2022-03-09">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2022-03-09to2022-03-09">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2022-03-09to2022-03-09">V5Z 1K5</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-03-09to2022-03-09">778</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-03-09to2022-03-09">331-0962</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-03-09to2022-03-09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-03-09to2022-03-09">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-03-09to2022-03-09">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-03-09to2022-03-09">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-03-09to2022-03-09">Common Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-03-09to2022-03-09">EPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-03-09to2022-03-09">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-03-09to2022-03-09">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=S? YW.E[.'$O7@7OYL,_P-02P,$%     @ FE9J5)^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( )I6:E2JDKHL200  $,1   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " ":5FI4GZ ;\+$"  #B#   #0              @ &,#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( )I6:E27BKL<P    !,"   +
M  "  6@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( )I6:E2JQ"(6,P$  "("
M   /              "  5$0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" ":5FI4)!Z;HJT   #X 0  &@              @ &Q$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " ":5FI499!YDAD!  #/ P
M$P              @ &6$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  #@$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="essa8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://essapharmaceuticals.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="essa8k.htm">essa8k.htm</File>
    <File>epi-20220309.xsd</File>
    <File>epi-20220309_lab.xml</File>
    <File>epi-20220309_pre.xml</File>
    <File>ex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "essa8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "essa8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "epi-20220309_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "epi-20220309_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "epi-20220309.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 122,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "EPI",
   "nsuri": "http://essapharmaceuticals.com/20220309",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "essa8k.htm",
      "contextRef": "From2022-03-09to2022-03-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://essapharmaceuticals.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "essa8k.htm",
      "contextRef": "From2022-03-09to2022-03-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://essapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001279569-22-000371-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001279569-22-000371-xbrl.zip
M4$L#!!0    ( )I6:E3U; -K0@,  !,,   0    97!I+3(P,C(P,S Y+GAS
M9+5637/:,! ]MS/]#ZJO'6$;FC00:*=)F@[3I$E#OMI+1]@+:+ E1Y*#DU]?
M2;:!@$. MC[)J_?>[DJ[:[<_97&$[D%(REG'\6N>@X %/*1LV'&N>OAS[[#;
M=="GCV]>(_VTWV*,CBE$80L=\0!WV8#OH^\DAA;Z"@P$45SLHVL2I<;"CVD$
M AWR.(E @=[(/;703LVO]Q'&:^A> PNYN+KH3G5'2B6RY;J3R:3&^#V9<#&6
MM8#'ZPGV%%&IG*IYF5<\Z]%/J0RFY'=WXT1^R"[H[1#87GK^LY$%-P0.OY%S
M];@S\GJ_QB-5'V6#7^/=RX<]_N/N(#Z@(FO>/,;>I7>6NVS+8 0Q0?HRF.PX
M)K\BO4FCQL70K7N>[]Z>GO0LSLF!K2RB;%P%]YO-IFMW2^@2,NN+J)1NN&:[
M3R1,E?4N78&G3"K"@B?X4$T)\^ =-]]\ J65T-T<2DMH" LX"4%MR.]=O:'Q
M=?_N?0E-)1X2DDSA R+[5K;8L'#L^;CAEQ0IU#)<&ZNA6#TD("L)^58%[<MY
M=TH *4DR(B(F :2*!B2R%6M8=:_A-77?11 #4\=<Q$<P(&FDP[M+240'%$('
M*2*&H$P)RD1KK"]<EC1AC.O*U^U76(PM2:@N;6UXU38UT!(\@DN=#C(+W7,O
MNC$X]Y#K$>(@&G:<?&D$M;R5#&% &;5^BS[S$39=E9IT]=)2VNXB>$XBE1">
ML8]VG0B0FF<3.=&&@EA GB'I<(,TVHPS"Z624AC* YL=8=E+%S! M@=;ICXZ
MCJ1F"CJ%;21@T'$@H;B\J-\ZLYHNG!)AE%>TH#WXQ<,H_)821 1+*DLC0HOP
M!(2BNH;GYD >.56&?C[G!AD_TD'N/\@X(OU-,]84B/YCJB=&?S['HE/<6:L4
M[XOMU-;9<J$06VK15?,SG_PG/+!2*RCF#9<\;$S8K^MA4\MD.(MTDR!F)[!9
M$"5OBR">G>)5$<CG"6:)\^6ZKE=^$5:ZKV2Z$"E96O!,:YMPEK\??Q&/%=LB
MH">7'2KA&B$C[1F=^HJ@7F+:=[E5B00\94H\V S7+))Y2OEBCV/CFUG\%UCO
M4DI6?B'F]^ OBJ/Z[V+;0)XOC;:;:^KE'U!+ P04    " ":5FI4+^*J8/\*
M  !LAP  %    &5P:2TR,#(R,#,P.5]L86(N>&ULS9U?4^NX&<;O.]/OH*8W
M[<P).0EM9V /N\/)@9W,LD!)SMFV.YT=Q1;!@R-1V8'P[2O9EF-+>FU#IY*X
M@& ]K_S(^D62_TC^],-^FZ)GPK.$T;/1].CC"!$:L3BAF[/1U^7X?#E?+$8H
MRS&-<<HH.1M1-OKA^]__#HF?3W\8C]%E0M+X%'UAT7A![]EWZ!IOR2GZD5#"
M<<[X=^@;3G=R"[M,4L+1G&V?4I(3D5#N^!3]]6@Z6Z/Q>$"^WPB-&?]ZMZCS
M?<CSI^QT,GEY>3FB[!F_,/Z8'45L.RS#98[S75;G]G'_L?HIPS^E"7T\E;_6
M."-('"^:G>ZSY&PD]UOM]N7XB/'-9/;QXW3RCY^OEM$#V>)Q0N5QB\A(1<E<
M;''3DY.329&JI(9RO^:IVL?Q1-FI<Q:I28>^X21+3K/"WA6+<%Y4>^]N$*B0
M_XV5;"PWC:>S\?'T:)_%(W7PBR/(64KNR#TJBGF:OSX)E+)$DC"JMCUP<F\W
MDW(^D?$32C8X)['<T8G<T?1O<D=_K#9?X35)1T@J!1]@N4Y:>55!$]=F;PE/
M6'Q!W^=:C_9D7WQW>/X_%* 9[[P(*Y;C]%WFFY'.;5^3]QWQ0YS[(RW:>?*^
M(]V(_+_8SDW+;SZ\]N.:RHU7XE/+(MGGH@,CL3(IL^AH@8L]%!U#E7>=.XM:
M^::R-6?<++OL&8L\,Q(=;=CS)":)R'LV_<]?Y,=Q^;$HNOCWMSD3HX'S=99S
M'.4JMZ(H9R-+^D2W)97G7'G#/.HI8*681$QT3T_Y."T/91E^S]G6NMNJY,R2
M^%NZKN/+0R-V 1AMR3C)V(Y'Y$TUTW0+':7*T385"CFL(G3\=3GZOM"@7Y7J
MWY\FAUP<5;88"NVVA.8KD:NE%.UD5U5M,Z5JNID61$5;#.GUK"1(:CQ4\KG8
M>2P-7*9X8RF"ENZJFJVV5#VW$H.H:)LCO:9K#9(BGU7]A6013Y[D\+ZK+"V9
M\XJWF#3JOZ$)"P/3&$Q#0^NQD;\CFT1V-=*&/.<E<F-'DP;H77<#G;;U?L$J
M#@*<(0[!GJ,9A.HHCRR=4[K#Z1UY8KP+H;;,-3DVDSHP34U0G%B,@7B46E2*
M/5+Q]YTXFR<\?>T%PU"Z9@.PJN.AR8(BQ.X-A*26^^=DQ3'-$MF8]8)B2IV?
MA@!FC5,231<4*X Y^%2EUONG9?E TE3>,\"TOV&QB5T3 QO6F3&505$#V@.Y
M*2)0%1(6.A?/<M0NADX#"]S0^P3(L-W%4"T.%B/=X4"2BC DXSS2U+AET<.1
MH71-$&!59T>3!46-W1O(2RE'A3X,4"YH/ B36N<'$LVF'9%*%" @;6=]> BU
M;S@NDRS":>GG4FS+.HIHT;J&!+2K@V((@X(%<@<"4P8H;HH0[]#\DV ^#)F&
MT@\PAE4[+K4L0%AT;WVH2+TW4.8[SEO.X=X'ECJ[F=MCMKZO"^B"@*7'G'&W
MMY2W8/'8&UW0/,E?Y?-XU[OMFG!+ 4V)*SX@<XH+/3T('@!3.@>E#$D=*H7>
M:E_=5:"Y?! 2+)(N<TN!W62;A+8F(!JLQ@ B#MKBN51O5,Q%*\5QNJ QV?]$
M7L&R&3JW7  VVV!HHH#(L#L#T*C$J% C(?<&QRU/MIB_+I.HI]LPA6[Q@(RV
M^=!5 0$"6 ,(J=1HN9C[[E56>+^(!;#)?5(^7]Y#"JAW"TR/[38W@#@@?+H=
M A2)(-2.\@W3@D:,/['&XQ)SMA.-X>N<Q?"(I2?*+5B#BM#&JS,D(,B&^ 10
M:X5^*)]I04S.#2HR0#(';]2=Q[$X6%GUYRJA9 H> ZO6+6$==MM<680!T02[
M QBJE!_4!R1CT T-"9S9&XH[\P_.;"@XLZ#!F;T'G-4+"PB<XS<4]]@_.,=#
MP3D.&ISC=X$C*M][FS,7'V_XBKW8'O@&E5ZP,:U:H3G(PD/&\-8'C R0XQL9
MXAN58K!UPV\Y>TYH! ^C(;D7: #35G(T;7CXV WV,50/DE6<;Y"JP7KOET7)
M_+0V;9/VIJ;4A =*VUAO(U.J?6-QR[(<I_]*GCI/TNUB+XA8#5M!:2G#P\5F
MKP^:,@:)(%\GW16V\@:(=;J:ENYNRK'%UF'*<2,Q"!!LCLPIQ^75E5+DHZHE
MJYQ@H&5H)SNK:(NINIX;:6%4LVG(J.7B^RTTOK[0<F69]/:!4?CA E/BJK8A
M<ZK&]?0@:ATPI==\(4.%SN.5>[G"169ORAMISGIZW4[=L:N$(&I8=V-TVRK=
M0XW^PI-<['W.MML=K>X,V9Y!!'2N:KK3IJIUJR@( KJ<Z3146M06>T!CR=(D
M2O*$;GX6)Z<\P;:2V42NH( -*B),11 X@+9T%@Y"I)0>0+CE1,)(1&44$P[E
M(D?\YO[>VOMWB5V!T6]8 0(K@P"EUYX.C @81XT(5(:@(L8_.HLLVQ'^)H L
M(9XP LT#,!GZ$)&"3/:"50;ZYFM)HIWH+U^GL_4JR5/;B:<I<=8_ >;JWDE+
M#X(/P)3.0Y&&V#V:SOZT_C-241X0N&8KCN6BMLO7[9JEP$I85I4K$#HL*A8L
MDB!P@'WI1%PS5$E1J?6U4E;+L*5(6KHK"*RV5/6W$H.H>)LCHQ%HU;?'YO]B
M'ST(8P28[&"7N>X&;";UKJ"I"0*##F/&R4HE14KK:[+#H0O;] \*-MX&!9N>
M0<$FQ$'!9NB@8.-U4*!V72Y3(MJHFW6:;#"P:&*GVC48'99U1BS2H'"!_8%M
M1QV"#C$^5MLLEEV3KQ+@V\+#I?A@*2F@<[;>9I?->L%-FR@(3KJ<&4MNE@OA
M-<1(JGVPL8N3G,2EH<N$8AHE.*V7;K1=/>\/<4;,0/,U/#WZ,#@:9M) J@Q3
M:RS6@8=E.'U<=B\?XOB%I.E/E+W0)<$9HR0NK[?8[BYUZ]T^==-CN_W@#2 .
M JDA#H'';V30^%%&(15672WS1M,WENYHCGDQAYW;6BA YY8>P&:;&DT4$"UV
M9P EM1B5:G^3PLO5*^J!5_G.)+"0D-SQ%/%.T]I,<:LV(&XZ#4+SQJLU1P[C
MY3+*XW3.G,AW723/Y O.<>4/+#,D=SV!L\NT/G/3I@T(HTZ#X%S-.D8N5X,5
M5UZ7K>%S,?S:L(ZGSS65^\5K#(OF^C6U)"!$;+XZ5K'A2&F]\;#<XC3]O,L2
M2C*X4])4;GFP6FSST)($Q(/-%\!#(45*ZXV'BRWA&]'=_<C92_Y0K2$+E@]0
MN^6CTW*;$ZLT(%ZZ_ '<J!!4QJAE?_T!M#\L@%ZN  F7UB)UC YH5N/&T(4$
M#63.("8ED;P><\URM&+H:T90_D#01?5:O>;*]64^/M^2$D5RPD4Y6J<QYC:,
MNL3.WY@"&C;>FV(H@X"IUQ[\#I4Z JD0#^3<")9Y\QRO,++(R1:<2=$?XHJB
MH>852WWZ((@::%+GJ@AKGW@7@4A&^EY5J;D@/SSL:XD<CY8M!K7!<D,1!">@
M+6BHW'R_@;_U_';K-(DN4X;AJS MC>-5_$Q[V@)^!T% %)BNH&7["B$JE-X8
M^(SI(]\]Y='K+6<1(?)IK:QNN?JNT0V,=LO-FXK4)FI0:$"LO<4O0.$A"]3(
MXT.C]_)]P4\^C"Y7F&/1X_(!BX-XL\LSV:,*<_ 5\\X@Q[<B!A1 NR'1$1$0
M?@-L0C<GBDA4A'Y 93!J1'L\;\L.JQ.2^//K';DG7,YI6)%]_EGL[+'CS&-
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M2P  /J8!  D   !E>#DY,2YH=&WM?6MOVV:V[G<!^@\\Q9F!#3!N["1M;CN
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M+<]S](KPBL(=P]V'<SQ;.?^2SB%^;06F!#X"#N%X-#&@:*?P*[#>YVC19OC
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M03.N&L/'>.^$CHJ]E?+;1_OHQL&=!9M\ES?RZ O>R"C?Y$(S#=BCJ/#G<I3
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M X8_-M?>)CF#L1/>OQ";3\AZ79JFHJA/-A7$&J=\W*5J,+EA:&>I)@*>P_*
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MR='#HT.TKF'('$)'LH6,KZJ=9.#5]WIHQX(,EK2G^OPN%[L[3WX;4 \O.3;
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M(DBXM?CI'C[$H4!4&'@;Z$UG30MZ:>K;6)(*SAP<(^+%L<(DY'3I/=;=!,,
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MD( +-,NINBA0?E_5Y/IAFW.%*XW*&%?H-/NT.T3&VYC31YS%LAJ/"G_-!5?
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M61CM>5VMSEB=KQI7?M"S(E_UM&Y5._(14=\"%]G9"64KL9<^ =LJ)X3D8M$
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MY8DO^G;5Y^$749^P!J) :>&_?_W;FW_1+_]Y^NLOK_X_4$L! A0#%     @
MFE9J5/5L VM" P  $PP  !               ( !     &5P:2TR,#(R,#,P
M.2YX<V102P$"% ,4    " ":5FI4+^*J8/\*  !LAP  %
M@ %P P  97!I+3(P,C(P,S Y7VQA8BYX;6Q02P$"% ,4    " ":5FI42_#8
M!UT'  #66   %               @ &A#@  97!I+3(P,C(P,S Y7W!R92YX
M;6Q02P$"% ,4    " ":5FI43W "R>\6  ")LP  "@              @ $P
M%@  97-S83AK+FAT;5!+ 0(4 Q0    ( )I6:E2SJ2B)_4L  #ZF 0 )
M          "  4<M  !E>#DY,2YH=&U02P4&      4 !0 Q 0  :WD

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
